CompletedNot applicableNCT02391831
Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy
Studying Spinal Muscular Atrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institut de Myologie, France
- Principal Investigator
- Laurent Servais, MDAssociation Institut de Myologie
- Intervention
- Strength, function and activity measurements(other)
- Enrollment
- 81 enrolled
- Eligibility
- 2-30 years · All sexes
- Timeline
- 2015 – 2018
Study locations (9)
- Reference centre for neuromuscular diseases - UZ Leuven - Department of Pediatrics - University Hospitals Leuven, Leuven, Belgium
- Centre de Référence neuromusculaire - CHR La Citadelle, Liège, Belgium
- Service de Rééducation Pédiatrique Infantile " L'Escale " - Hôpital Femme Mère Enfant, Bron, France
- Maladie Neuromusculaire de l'enfant - Service Maladies infectieuses et neurologie infantile - Hôpital Roger Salengro, Lille, France
- Centre de référence Maladies Neuromusculaires Nantes-Angers - Hôtel Dieu, Nantes, France
- I-Motion Institute - Trousseau Hospital, Paris, France
- Neuropédiatrie - Service de Pédiatrie 1 - CHU Hautepierre, Strasbourg, France
- Unité de neurologie pédiatrique - Hôpital des enfants, Toulouse, France
- Universitätsklinikum Essen (AöR) - Klinik für Kinderheilkunde I - Sozialpädiatrisches Zentrum, Essen, Germany
Collaborators
Institut Roche
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02391831 on ClinicalTrials.govOther trials for Spinal Muscular Atrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07488338HABIT-ILE + FST in Children With SMA: Preliminary EffectivenessTeachers College, Columbia University
- RECRUITINGNCT07400198Gait and Bone Health in SMAJacqueline Montes
- RECRUITINGPHASE1, PHASE2NCT07070999Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1Gemma Biotherapeutics
- RECRUITINGNANCT07321977Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic VolunteersInstitut de Myologie, France
- RECRUITINGPHASE2NCT07287982A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophyargenx
- RECRUITINGNANCT07286565Active NBS Study: Decentralised Monitoring Motor Development in Children With Duchenne Muscular Dystrophy or Spinal Muscular Atrophy Identified by Newborn ScreeningCentre Hospitalier Universitaire de Liege
- RECRUITINGNCT06532474Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed TherapiesSt. Jude Children's Research Hospital
- RECRUITINGPHASE3NCT07265232Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).Lantu Biopharma